REGN monthly performance report
Check REGN's monthly returns, drawdown, and seasonality trends — updated every month.
REGN monthly report
—
Key takeaways
- Regeneron Pharmaceuticals (REGN) closed November 2026 at $955.47, up 2.97% for the month and +37.48% over the trailing 12 months.
- Year-to-date, REGN is +23.79%, outperforming the S&P 500 which has returned +10.62% YTD.
- The stock is trading +27.83% versus its 200-day moving average ($747.48), a bullish technical signal.
- Over the past three years, REGN has underperformed the S&P 500 by −51.45%, with a relative strength index reading of 70.
- Win rate over the trailing 39 months stands at 51.3% — 20 positive months versus 19 negative months.
Regeneron Pharmaceuticals ended November 2026 at $955.47, posting a monthly return of +2.97%. The S&P 500 returned −0.18% over the same window, leaving relative performance at +3.15%.
The current quarter stands at +26.01% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +27.83% versus the 200-day moving average ($747.48).
Year-to-date, REGN is +23.79% against SPY +10.62%, a gap of +13.16%. The stock is currently −3.66% below its 52-week high, with maximum 3-year drawdown at −59.80%.
| Period | REGN | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.45% | −0.36% | +0.81% |
| 1 Week | +5.65% | +2.59% | +3.06% |
| 1 Month | +2.97% | −0.18% | +3.15% |
| 3 Months | +18.55% | −2.37% | +20.92% |
| 6 Months | +34.03% | +0.83% | +33.20% |
| YTD | +23.79% | +10.62% | +13.16% |
| 12 Months | +37.48% | +12.25% | +25.23% |
| 3 Years | +19.93% | +71.37% | −51.45% |
| Rank | Month | Return |
|---|---|---|
| #1 | Oct 2026 | +22.37% |
| #2 | Jul 2026 | +22.31% |
| #3 | Nov 2025 | +19.70% |
| #4 | Oct 2025 | +15.92% |
| #5 | May 2024 | +10.05% |
| Rank | Month | Return |
|---|---|---|
| #1 | Oct 2024 | −20.27% |
| #2 | May 2025 | −18.12% |
| #3 | May 2026 | −13.05% |
| #4 | Sep 2024 | −11.26% |
| #5 | Nov 2024 | −10.50% |
| Quarter | Return |
|---|---|
| Q3 2025 | +7.10% |
| Q4 2025 | +37.28% |
| Q1 2026 | +0.10% |
| Q2 2026 | −19.30% |
| Q3 2026 | +21.61% |
| Q4 2026 (QTD) | +26.01% |
| Year | Return |
|---|---|
| 2023 | +21.73% |
| 2024 | −18.90% |
| 2025 | +8.36% |
| 2026 | +23.79% |
| Metric | Value |
|---|---|
| 52-Week High | $991.73 (2026-11-04) |
| 52-Week Low | $591.52 (2026-06-02) |
| Current Price | $955.47 |
| 200-Day Moving Average | $747.48 |
| Price vs 200DMA | +27.83% |
| 3-Year Maximum Drawdown | −59.80% (2025-06-05) |
| Current Drawdown from 52W High | −3.66% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 70 |
| 3-Year Excess Return vs S&P 500 | −51.45% |
| RS Peak | 118.7 (Aug 2024) |
| RS Trough | 43.8 (Jun 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was REGN's return for this report period?
REGN returned +2.97% in the latest monthly window ending 2026-11-13.
Has REGN outperformed SPY year to date?
YTD REGN: +23.79% vs SPY: +10.62%.
What is REGN's 12-month return?
+37.48% over the trailing 12 months.
Is REGN above or below its 200-day moving average?
Price is +27.83% versus 200DMA ($747.48).
What is the maximum drawdown in the 3-year window?
−59.80% on 2025-06-05.